Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Amphix Bio
AddedFeb 18, 2024
UpdatedJun 18, 2026
Amphix Bio

Amphix Bio

Angel

Amphix Bio: Innovating in materials science and stem cell biology for novel therapeutic development.

HQ
Chicago, IL, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Amphix Bio, founded with a mission to advance regenerative medicine, focuses on developing innovative therapeutics to enhance healing post-traumatic injury and extend human healthspans. The company specializes in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics. Amphix Bio offers a unique cell-free therapy that activates regenerative biological signals and provides scaffolds for tissue growth, targeting the regenerative medicine market.

Notable figures associated with Amphix Bio include experts in various scientific disciplines, though specific names are not provided. The company has achieved significant milestones in preclinical and clinical trials, demonstrating promising results for its novel therapies. Amphix Bio's impact lies in its potential to revolutionize regenerative medicine by offering advanced therapeutic solutions that promote healing and improve quality of life.

Amphix Bio - Similar Companies

Amplicore logo

Amplicore

Axent Biosciences logo

Axent Biosciences

AgeX Therapeutics logo

AgeX Therapeutics

Amplifica logo

Amplifica

amplificabio.com

APstem Therapeutics logo

APstem Therapeutics

apstemtx.com

Appia Bio logo

Appia Bio

appiabio.com

BioRegenx logo

BioRegenx

bioregenx.com

Ampersand Biomedicines logo

Ampersand Biomedicines

ampersand.bio

CarthroniX logo

CarthroniX

carthronix.com

42Bio logo

42Bio

42bio.com

Regenerative Bio logo

Regenerative Bio

regen-bio.us

AmplifyBio logo

AmplifyBio

Autobahn Therapeutics logo

Autobahn Therapeutics

autobahntx.com

Stemson Therapeutics logo

Stemson Therapeutics

stemsontx.com

Amnio Technology logo

Amnio Technology

Amphix Bio - Quick Facts

Who are Amphix Bio's competitors?

Companies similar to Amphix Bio include Amplicore, Axent Biosciences, AgeX Therapeutics and Amplifica.

When was Amphix Bio founded?

Amphix Bio was founded in 2019.

Where is Amphix Bio's headquarters located?

Amphix Bio's headquarters is located in Chicago, IL, US.

When was Amphix Bio's last funding round?

Amphix Bio's most recent funding round was for $252.9k (USD) in February 2022.

How much has Amphix Bio raised to-date?

As of Feb 24, 2022, Amphix Bio has raised a total of $252.9k (USD).

How many employees does Amphix Bio have?

Amphix Bio has 8 employees as of Feb 4, 2024.

Amphix Bio - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
  • Government
Main Product
  • Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software